Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity
Y. Shimada et al., Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity, EUR J CANC, 36(8), 2000, pp. 987-993
The aim of this study was to evaluate whether cisplatin sensitivity relates
to patient's prognosis in oesophageal squamous cell carcinoma and to find
a useful chemosensitivity molecular marker. 59 oesophageal squamous cell ca
rcinoma (SCC) patients received cisplatin 30 mg/m(2)/week treatment of two
to five cycles, followed by oesophagectomy. We analysed retrospectively whe
ther the histological effect was related to patient's prognosis. Furthermor
e, to evaluate the relationship between the effect of preoperative cisplati
n treatment and p53 and cyclin D1 expression, we investigated p53 and cycli
n D1 expression in pretreatment biopsy samples using an immunohistochemical
analysis and compared the results with the histological effect to cisplati
n in the resected oesophagus. The cases that showed immunohistochemical p53
staining in the pretreatment biopsy samples were resistant to cisplatin (P
=0.032). However, there was no relationship between cyclin DI expression an
d histological effect (P=0.230). Nevertheless, combined analysis of p53 and
cyclin D1 can predict histological effect (P= 0.032). The prognosis of cis
platin-sensitive cases was significantly better than that of cisplatin-resi
stant cases (P=0.041). Cox's multivariate analysis revealed that the histol
ogical effect was an independent prognostic factor. In contrast, p53 protei
n accumulation and cyclin D1 were not. Histological response after neoadjuv
ant cisplatin treatment is a prognostic factor for oesophageal SCC and cisp
latin chemotherapy may be selected according to the findings of p53 and cyc
lin D1 expression. (C) 2000 Elsevier Science Ltd. All rights reserved.